New Strategy of Treatment for Esophageal Squamous Cell Carcinoma Using Immunotoxin Which Reacts to Epidermal Growth Factor Receptor

  • Soji Ozawa
  • Masakazu Ueda
  • Norifumi Hirota
  • Nobutoshi Ando
  • Masaki Kitajima
Conference paper


Squamous cell carcinoma is by far the most common neoplasm of the esophagus and the survival rate of its patients is generally low [1]. To treat this cancer more effectively, it is necessary to develop a strategy of targeted cancer therapy. Most squamous carcinoma cells hyperproduce epidermal growth factor (EGF) receptor [2, 3], and EGF in turn promotes the growth of EGF receptor-hyperproducing squamous carcinoma cells in vivo [4]. Moreover, an elevated EGF receptor level is a significant prognostic factor for patients with esophageal squamous cell carcinoma [5]. Therefore, since EGF and its receptor system play an important role in the growth of this cancer, EGF receptor is an ideal cell surface object for targeted therapy. We synthesized an immunotoxin consisting of murine monoclonal antibody (B4G7) against human EGF receptor and gelonin, a 60s ribosome-inactivating protein. We studied the cytotoxic effects of the immunotoxin on squamous carcinoma cells and tumors, and investigated the possibility of it as a new treatment for squamous cell carcinoma.


Epidermal Growth Factor Receptor Squamous Cell Carcinoma Human Epidermal Growth Factor Receptor Esophageal Squamous Cell Carcinoma Squamous Carcinoma Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Adkins PC (1981) Tumors of the esophagus. In: Sabiston DC (ed) Textbook of surgery: The biological basis of modern surgical practice, vol 1, edn 12. WB Saunders, Philadelphia, pp 841–855Google Scholar
  2. 2.
    Hunts J, Ueda M, Ozawa S, Abe O, Pastan I, Shimizu N (1985) Hyperproduction and gene amplification of the epidermal growth factor receptor in squamous cell carcinomas. Jpn J Cancer Res (Gann) 76: 663–666Google Scholar
  3. 3.
    Ozawa S, Ueda M, Ando N, Abe O, Shimizu N (1988) Epidermal growth factor receptors in cancer tissues of esophagus, lung, pancreas, colorectum, breast, and stomach. Jpn J Cancer Res (Gann) 79: 1201–1207PubMedCrossRefGoogle Scholar
  4. 4.
    Ozawa S, Ueda M, Ando N, Abe O, Hirai M, Shimizu N (1987) Stimulation by EGF of the growth EGF receptor-hyperproducing tumor cells in athymic mice. Int J Cancer 40: 706–710PubMedCrossRefGoogle Scholar
  5. 5.
    Ozawa S, Ueda M, Ando N, Shimizu N, Abe O (1989) Prognostic significance of epidermal growth factor receptor in esophageal squamous cell carcinomas. Cancer 63: 2169–2173PubMedCrossRefGoogle Scholar
  6. 6.
    Ozawa S, Ueda M, Ando N, Abe O, Minoshima S, Shimizu N (1989) Selective killing of squamous carcinoma cells by an immunotoxin that recognizes the EGF receptor. Int J Cancer 43: 152–157PubMedCrossRefGoogle Scholar
  7. 7.
    Hirota N, Ueda M, Ozawa S, Abe O, Shimizu N (1989) Suppression of an epidermal growth factor receptor-hyperproducing tumor by an immunotoxin conjugate of gelonin and a monoclonal anti-epidermal growth factor receptor antibody. Cancer Res 49: 7106–7109PubMedGoogle Scholar
  8. 8.
    Downward J, Yarden Y, Mayes E, Scrace G, Totty N, Stockwell P, Ullrich A, Schlessinger J, Waterfield MD (1984) Close similarity of epidermal growth factor receptor and v-erb B oncogene protein sequences. Nature 307: 521–527PubMedCrossRefGoogle Scholar
  9. 9.
    Hertler AA, Frankel AE (1989) Immunotoxins: A clinical review of their use in the treatment of malignancies. J Clin Oncol 7: 1932–1942PubMedGoogle Scholar

Copyright information

© Springer-Verlag Tokyo 1993

Authors and Affiliations

  • Soji Ozawa
  • Masakazu Ueda
  • Norifumi Hirota
  • Nobutoshi Ando
  • Masaki Kitajima
    • 1
  1. 1.Department of SurgeryKeio University School of MedicineShinjuku-ku, Tokyo, 160Japan

Personalised recommendations